Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Related Post
31 July, 2025
World Lung Cancer Day: Focus on the TROG Lung Working Party
TROG WORKING PARTY IN FOCUS: 31 July 2025 To
29 July, 2025
TROG 21.07 SOCRATES HCC Trial Expands Outreach
TRIAL IN FOCUS: 29 July 2025 We’ve extended the
